Success Stories: NAILG Secures Swift EB2-NIW Approval for a Chinese PhD Candidate Advancing AI in Drug Development
On May 14th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a PhD Candidate in the Field of Artificial Intelligence for Drug Development (Approval Notice).
General Field: Artificial Intelligence for Drug Development
Position at the Time of Case Filing: PhD Candidate
Country of Origin: China
State of Residence at the time of filing: Georgia
Approval Notice Date: May 14th, 2025
Processing Time: 2 months and 7 days (Premium Processing Requested)
Case Summary:
A highly accomplished PhD candidate from China sought assistance from North America Immigration Law Group (NAILG) for his I-140 EB2-NIW (National Interest Waiver) petition. When he approached our law firm, we immediately recognized the exceptional promise of his research. His groundbreaking work in artificial intelligence applied to drug development required a carefully crafted petition that would demonstrate his extraordinary ability and the national importance of his contributions to the U.S. healthcare system.
The petition was upgraded to premium processing, which led to a swift approval of the client’s I-140 EB2-NIW petition. This showcases the strength of the petition and NAILG’s expert advocacy
Innovative Applications of Artificial Intelligence in Drug Development
Our client’s research focuses on developing advanced AI models and algorithms to improve early disease diagnosis and predict patient responses to new drugs and combination therapies. By enhancing the precision of diagnostics and the effectiveness of treatments, his work aims to accelerate drug discovery and optimize healthcare outcomes, particularly benefiting vulnerable populations such as infants and the elderly.
Key Accomplishments Underscoring Exceptional Ability
The client’s petition presented the following significant achievements:
- Authored 5 peer-reviewed journal articles, including 3 first- or co-first-authored papers, and 1 first-authored conference article in prestigious AI and clinical medicine publications, and 2 first-authored preprints
- Received 256 citations, highlighting the scholarly influence and ongoing relevance of his work.
- Conducted 50+ peer reviews for leading journals and conferences in AI and machine learning, reflecting his recognized expertise.
- Secured research support from major funding bodies such as the National Science Foundation (NSF), National Institutes of Health (NIH), and European Research Council (ERC).
Strong Endorsement from Experts
The petition included four recommendation letters, including three independent advisory opinions from leading experts. These letters affirm the pioneering nature and significant impact of his research in AI for drug development. One expert stated:
“In summary, [client] is conducting cutting-edge research into multi-therapy drug development. The high quality of his research is clearly shown by his work reviewing the research of his academic counterparts. [Client’s] research in the artificial intelligence for drug development field is undoubtedly of benefit to both U.S. and global research communities.”
Swift NIW Approval in Just 2 Months and 7 Days
The client’s I-140 EB2-NIW (National Interest Waiver) petition was approved within a remarkable timeframe of 2 months and 7 days with the premium processing, showcasing both the client’s outstanding qualifications and the effectiveness of the petition prepared by NAILG.
We extend our congratulations and eagerly anticipate his continued impact on the field of artificial intelligence in drug development and public health advancements.